This page has beta status

BMBS COST Action B26
Obstructive Sleep Apnea

The main objectives of the COST Action B26 are:

(i) to assess the role of OSAS as a possible cause of increased cardiovascular risk.

Collaboration among different countries will provide a critical mass of data in both

untreated and treated patients, and result in the development of guidelines on preventive


(ii) to coordinate studies on pathogenetic mechanisms of increased cardiovascular risk of

OSAS (i.e., inflammation, oxidative stress, endothelial dysfunction, metabolic

derangements, altered autonomic control associated with exposure to intermittent hypoxia).

These studies will highlight possible factors susceptible to correction by therapy.

Secondary objectives are to promote exchanges between groups in the following fields:

(i) diagnosis of OSAS and patient management: guidelines exists on diagnosis of OSAS, but

evaluation of cardiovascular risk factors is not routinely performed in OSAS patients. The

joint effort of several groups will be helpful in setting up a useful and cost-effective

European protocol to longitudinally evaluate cardiovascular risk in OSAS patients;

(ii) excessive daytime somnolence (EDS) and medico-legal implications of OSAS: Problems

still exist on the assessment of EDS in OSAS. OSAS increases the risk of car accidents, but

legislation addresses the problem in different ways throughout Europe. A European

Network will contribute in developing guidelines and promotion of their application in

European countries. In this respect, the COST Action B26 will be complementary to the

ongoing FP6 Integrated Project on sleepiness entitled: “Advanced sensor development for

attention, stress, vigilance and sleep/wakefulness monitoring” (acronym: SENSATION,

project number: 507231);

(iii) establish a common protocol to be adopted by all participating Centres for data collection at

baseline and during clinical follow-up of treated and untreated OSAS patients, in order to

cross-sectionally and prospectively assess the association between OSAS and

cardiovascular morbidity in a sufficiently large patient sample representative of the

European population.

(Descriptions are provided by the Actions directly via e-COST.)

General Information*

Chair of the Action:


Vice Chair of the Action:

Prof Patrick LEVY (FR)

Science officer of the Action:


Administrative officer of the Action:

Ms Gabriela CRISTEA


Action Fact Sheet

Download AFS as .RTF


Last updated: 02 May 2011 top of page